Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (BRI LC03-01)
<p>Abstract</p> <p>Background</p> <p>A randomized trial of vinorelbine plus gemcitabine followed by docetaxel (VGD) versus paclitaxel plus carboplatin (PC) in patients with advanced non-small-cell lung cancer showed no difference in overall survival (median survival tim...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2011-08-01
|
| Series: | BMC Cancer |
| Online Access: | http://www.biomedcentral.com/1471-2407/11/356 |
| _version_ | 1828214257621139456 |
|---|---|
| author | Shinkai Tetsu Kubota Kaoru Origasa Hideki Teramukai Satoshi Tokoro Akihiro Tada Harue Kawahara Masaaki Fukushima Masanori Furuse Kiyoyuki |
| author_facet | Shinkai Tetsu Kubota Kaoru Origasa Hideki Teramukai Satoshi Tokoro Akihiro Tada Harue Kawahara Masaaki Fukushima Masanori Furuse Kiyoyuki |
| author_sort | Shinkai Tetsu |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>A randomized trial of vinorelbine plus gemcitabine followed by docetaxel (VGD) versus paclitaxel plus carboplatin (PC) in patients with advanced non-small-cell lung cancer showed no difference in overall survival (median survival time: 13.6 versus 14.1 months) between the two treatment groups. We report here the results of quality-of-life (QOL) study initiated in the mid-course of this randomized trial.</p> <p>Methods</p> <p>The patients themselves assessed the Functional Assessment of Cancer Therapy (FACT)-Lung (FACT-L), FACT-Taxane and the Functional Assessment of Chronic Illness Therapy - Spirituality (FACIT-Sp) QOL instruments at baseline and 6, 12 and 18 weeks after the treatment. The primary endpoint was a comparison of total QOL score for each assessment instrument between the two groups.</p> <p>Results</p> <p>Sixty-eight patients from the trial (VGD, 34; PC, 34) who submitted baseline questionnaires and at least one questionnaire over the course of treatment were eligible. Longitudinal analysis showed a significant difference in slope of the FACT-Taxane score (p = 0.004) between treatment regimens over time, but no difference was found in FACT-L score (p = 0.311) and FACIT-Sp score (p = 0.466) between the two groups.</p> <p>Conclusions</p> <p>The significant difference in slope of FACT-Taxane score favored the VGD regimen. These data should be considered in treatment decision-making for patients with advanced non-small-cell lung cancer.</p> <p>Trial registration</p> <p><a href="http://www.clinicaltrials.gov/ct2/show/NCT00242983">NCT00242983</a>.</p> |
| first_indexed | 2024-04-12T15:01:37Z |
| format | Article |
| id | doaj.art-dcc95712b44e45c3aedd6f60bde3f9f2 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-04-12T15:01:37Z |
| publishDate | 2011-08-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-dcc95712b44e45c3aedd6f60bde3f9f22022-12-22T03:28:04ZengBMCBMC Cancer1471-24072011-08-0111135610.1186/1471-2407-11-356Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (BRI LC03-01)Shinkai TetsuKubota KaoruOrigasa HidekiTeramukai SatoshiTokoro AkihiroTada HarueKawahara MasaakiFukushima MasanoriFuruse Kiyoyuki<p>Abstract</p> <p>Background</p> <p>A randomized trial of vinorelbine plus gemcitabine followed by docetaxel (VGD) versus paclitaxel plus carboplatin (PC) in patients with advanced non-small-cell lung cancer showed no difference in overall survival (median survival time: 13.6 versus 14.1 months) between the two treatment groups. We report here the results of quality-of-life (QOL) study initiated in the mid-course of this randomized trial.</p> <p>Methods</p> <p>The patients themselves assessed the Functional Assessment of Cancer Therapy (FACT)-Lung (FACT-L), FACT-Taxane and the Functional Assessment of Chronic Illness Therapy - Spirituality (FACIT-Sp) QOL instruments at baseline and 6, 12 and 18 weeks after the treatment. The primary endpoint was a comparison of total QOL score for each assessment instrument between the two groups.</p> <p>Results</p> <p>Sixty-eight patients from the trial (VGD, 34; PC, 34) who submitted baseline questionnaires and at least one questionnaire over the course of treatment were eligible. Longitudinal analysis showed a significant difference in slope of the FACT-Taxane score (p = 0.004) between treatment regimens over time, but no difference was found in FACT-L score (p = 0.311) and FACIT-Sp score (p = 0.466) between the two groups.</p> <p>Conclusions</p> <p>The significant difference in slope of FACT-Taxane score favored the VGD regimen. These data should be considered in treatment decision-making for patients with advanced non-small-cell lung cancer.</p> <p>Trial registration</p> <p><a href="http://www.clinicaltrials.gov/ct2/show/NCT00242983">NCT00242983</a>.</p>http://www.biomedcentral.com/1471-2407/11/356 |
| spellingShingle | Shinkai Tetsu Kubota Kaoru Origasa Hideki Teramukai Satoshi Tokoro Akihiro Tada Harue Kawahara Masaaki Fukushima Masanori Furuse Kiyoyuki Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (BRI LC03-01) BMC Cancer |
| title | Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (BRI LC03-01) |
| title_full | Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (BRI LC03-01) |
| title_fullStr | Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (BRI LC03-01) |
| title_full_unstemmed | Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (BRI LC03-01) |
| title_short | Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (BRI LC03-01) |
| title_sort | quality of life evaluation for advanced non small cell lung cancer a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial japan multinational trial organization lc00 03 bri lc03 01 |
| url | http://www.biomedcentral.com/1471-2407/11/356 |
| work_keys_str_mv | AT shinkaitetsu qualityoflifeevaluationforadvancednonsmallcelllungcanceracomparisonbetweenvinorelbineplusgemcitabinefollowedbydocetaxelversuspaclitaxelpluscarboplatinregimensinarandomizedtrialjapanmultinationaltrialorganizationlc0003brilc0301 AT kubotakaoru qualityoflifeevaluationforadvancednonsmallcelllungcanceracomparisonbetweenvinorelbineplusgemcitabinefollowedbydocetaxelversuspaclitaxelpluscarboplatinregimensinarandomizedtrialjapanmultinationaltrialorganizationlc0003brilc0301 AT origasahideki qualityoflifeevaluationforadvancednonsmallcelllungcanceracomparisonbetweenvinorelbineplusgemcitabinefollowedbydocetaxelversuspaclitaxelpluscarboplatinregimensinarandomizedtrialjapanmultinationaltrialorganizationlc0003brilc0301 AT teramukaisatoshi qualityoflifeevaluationforadvancednonsmallcelllungcanceracomparisonbetweenvinorelbineplusgemcitabinefollowedbydocetaxelversuspaclitaxelpluscarboplatinregimensinarandomizedtrialjapanmultinationaltrialorganizationlc0003brilc0301 AT tokoroakihiro qualityoflifeevaluationforadvancednonsmallcelllungcanceracomparisonbetweenvinorelbineplusgemcitabinefollowedbydocetaxelversuspaclitaxelpluscarboplatinregimensinarandomizedtrialjapanmultinationaltrialorganizationlc0003brilc0301 AT tadaharue qualityoflifeevaluationforadvancednonsmallcelllungcanceracomparisonbetweenvinorelbineplusgemcitabinefollowedbydocetaxelversuspaclitaxelpluscarboplatinregimensinarandomizedtrialjapanmultinationaltrialorganizationlc0003brilc0301 AT kawaharamasaaki qualityoflifeevaluationforadvancednonsmallcelllungcanceracomparisonbetweenvinorelbineplusgemcitabinefollowedbydocetaxelversuspaclitaxelpluscarboplatinregimensinarandomizedtrialjapanmultinationaltrialorganizationlc0003brilc0301 AT fukushimamasanori qualityoflifeevaluationforadvancednonsmallcelllungcanceracomparisonbetweenvinorelbineplusgemcitabinefollowedbydocetaxelversuspaclitaxelpluscarboplatinregimensinarandomizedtrialjapanmultinationaltrialorganizationlc0003brilc0301 AT furusekiyoyuki qualityoflifeevaluationforadvancednonsmallcelllungcanceracomparisonbetweenvinorelbineplusgemcitabinefollowedbydocetaxelversuspaclitaxelpluscarboplatinregimensinarandomizedtrialjapanmultinationaltrialorganizationlc0003brilc0301 |